Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and ...
Fierce Biotech

Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. | Lynk Pharmaceuticals has reported ...

Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data

CEO Todd Harris said the company has narrowed its focus to what he described as the “highest value opportunities” for its selective FGFR3 inhibitor dabogratinib, emphasizing indications where FGFR3 ...